Proposition 38: A voter guide to the $8.4 billion immunology bond

What Proposition 38 does

Proposition 38 would authorize $8.4 billion in state general obligation bonds to fund immunology and immunotherapy research. The bond proceeds are split in two equal parts: half would support a single University of California–affiliated nonprofit medical research institute that meets specific criteria, and the other half would be distributed as competitive research grants to California public universities and nonprofit research institutions through an advisory council.

A key feature claimed by supporters is a built‑in mechanism intended to pay for the bond over time: ten percent of revenue from licensing successful immunotherapies would be returned to California to offset the bond costs, and therapies developed through this research that are sold within California must generally be offered to patients at a 20% discount.

Official summaries describe a total bond cost of about $12 billion when interest is included. The intended annual debt service is estimated at roughly $500 million to $600 million for about 20 years, a cost that remains subject to the timing of issuance and interest rates.

The measure also imposes governance and reporting requirements intended to provide accountability and transparency over how funds are spent and what results are produced.

Who wrote Prop. 38 and which institute would receive half the funds

California’s public reporting has identified the author as Gary K. Michelson, a billionaire inventor who wrote Prop. 38 and has been described as the measure’s primary donor. The California Institute for Immunology and Immunotherapy is described in CalMatters’ reporting as the only institute currently meeting the statutory criteria to receive half the bond proceeds; the same reporting notes the institute’s primary funder is Michelson, who also funded the ballot campaign.

An affiliation arrangement between the UCLA system and the proposed institute was disclosed: UCLA would receive a 7.5% net‑revenue share from outcomes tied to the institute’s work, and four senior UCLA officials sit on the institute’s board. Readers should view these facts as reported findings rather than policy judgments about intent.

“Reporting by CalMatters found only one institute in California currently meets those criteria: the California Institute for Immunology and Immunotherapy. The institute’s primary funder was billionaire Gary K. Michelson, who wrote Prop. 38 and was by far the largest donor to its political campaign.”

How the bond money is distributed

The 50/50 allocation splits the funds between the designated institute and competitive grants to California universities and nonprofits. Of the total, at least $4.2 billion is set aside specifically for research on cancer, heart disease, and Alzheimer’s disease, a disease set-aside that shapes the understanding of the 50/50 split.

The designated institute must strive to generate revenue from its work, and ten percent of that revenue would return to the state General Fund until the bond is repaid. The remaining grant funds are awarded through a process overseen by an advisory council, with grant recipients obligated to purchase a portion of goods and services from California suppliers where feasible.

California property owners, taxpayers, and program participants should note that the discount provision applies to therapies developed with Prop. 38 funds that are sold in California; the official text says therapies “generally” must be offered at a 20% discount, a nuance that has been the subject of debate.

Fiscal impact and cost to taxpayers

The Financial impact is framed by the Legislative Analyst’s Office (LAO) as a long‑term annual burden of about $500 million to $600 million for roughly 20 years to repay the bond, equating to about 0.25% of the state’s General Fund budget in the baseline estimates. The broader cost to the General Fund includes interest, which makes the total outlay higher than the upfront amount.

Supporters argue the measure could pay for itself through licensing revenue and the 10% General Fund return. Opponents counter that the revenue target to break even—often cited as around $120 billion over 20 years—depends on uncertain market outcomes and is not guaranteed.

Criticisms and drawbacks

Critics emphasize that borrowing is a controversial way to fund research and that the mechanism is narrow in scope. The LAO context notes the general fund share and the additional cost from interest, while opponents highlight that public universities and nonprofits outside the designated framework may be excluded from most of the funding, limiting the breadth of California’s biomedical research ecosystem.

The measure’s structure—requiring half of the funds to go to a single institute and limiting eligibility for the remainder—has been pointed to as a potential bottleneck for California researchers who do not meet the criteria. Critics of ballot‑box science argue that this approach can privilege visible topics over broader scientific opportunities and public health needs.

The proposal has prompted discussion of alternatives. Notably, a contemporary priority is to compare Prop. 38 with other financing approaches, including a broader 2028 science bond that would fund a wider range of research areas and a proposed NIH‑style state research agency advanced by some policymakers. Supporters say the measure secures steady, targeted funding for immunology, while opponents favor more flexible budgeting and competitive grant processes.

Oversight, accountability, and implementation questions

Prop. 38 outlines annual public reporting and independent audits for both the designated institute and the grant council. However, there are ongoing questions about capacity and spending trajectories at the designated institute, including reported headcount and expenditure figures that have been cited in coverage of the measure’s implementation: publicly reported staffing levels (as of September, only a handful of employees vs. the planned expansion), and a multi‑year cost trajectory that some observers say may outpace early spending projections.

A concrete implementation question often asked by voters: can the designated institute absorb $4.2 billion and deliver credible revenue projections? The figures cited in reporting—such as hundreds of millions of dollars in personnel and construction costs by mid‑2026 and a comparatively small amount spent to date—are closely tracked in public analyses.

Money, endorsements, and current status

Campaign finance tallies show a significant funding advantage for proponents in the period leading up to a vote. Backers include prominent patient advocacy groups and scientific organizations. Notably, Governor Gavin Newsom and the California Democratic Party have endorsed Prop. 38, as has the state GOP, along with dozens of patient and research groups. The campaign cited substantial fundraising leadership, including the Michelson connection.

On the no side, advocacy and scholarly voices have highlighted concerns about the measure’s financing, governance, and potential bias toward a single beneficiary institution. As reporting and polling have shown, supporters and opponents have argued over the measure’s costs and long‑term implications.

Polling data cited in coverage indicated a plurality of support among likely voters at certain times, with figures such as approximately 57% support reported by PPIC in some readings, and contemporaneous reporting noting a near‑term lead for Prop. 38 in the morning after the vote tally (e.g., 56% to 44% in early results). Status updates are time‑sensitive and should be checked against official election results.

How Prop. 38 compares to other science funding options

A distinct contemporaneous option is a larger 2028 bond package pledged to a broader science portfolio—covering biomedical research, wildfire prevention, water supply—and possibly modeled after a broader state research agency concept proposed by lawmakers. This context matters because it frames Prop. 38 as a choice between a targeted immunology program and broader, more flexible science funding strategies.

The debate often centers on whether general‑obligation financing for research should be used for targeted topics or directed through a flexible, competitive, statewide framework. Proponents contend that a focused program could preserve California’s leadership in immunology and immunotherapy, while opponents argue for broader coverage, market-driven development, and governance that avoids long‑term debt tied to a single field.

Official voter information and where to read the ballot text

Readers seeking primary sources can consult the California Secretary of State’s voter information guides and the Legislative Analyst’s Office for the official fiscal impact. Useful references include the Secretary of State’s Proposition 38 page and the LAO analysis.

For broader context, non‑partisan resources such as Ballotpedia, CalMatters, and the League of Women Voters Easy Voter Guide provide summaries and additional materials.

Official text excerpt: “AUTHORIZES BONDS FOR IMMUNOLOGY MEDICAL RESEARCH. INITIATIVE STATUTE. Authorizes $8.4 billion in general obligation bonds for immunology and immunotherapy research, half to a single University of California–affiliated nonprofit medical research institute, half to research grants.” Source: California Secretary of State

What your vote would mean

YES on Prop. 38 would authorize the $8.4 billion bond, directing half of the funds to a single designated institute and the other half to competitive grants for California universities and nonprofits. It includes governance and reporting requirements, the 10% royalty back to the General Fund, and a 20% discount on therapies developed with these funds when sold in California.

NO on Prop. 38 opposes issuing the bonds, arguing that this approach locks in long‑term debt for a narrow focus and constrains the state’s flexibility to address evolving health priorities. It also frames the policy as an instance of “ballot‑box science,” where funding decisions are driven by a ballot measure rather than a prioritized, comprehensive plan.

Myth vs. fact (illustrative contrast)

No net cost to taxpayers is claimed by supporters, but LAO analysis shows a long‑term debt service of roughly $500–$600 million annually for about 20 years, plus interest. This difference matters because it affects California’s fiscal flexibility. The claim that the program would pay for itself through licensing revenue hinges on uncertain outcomes and an ambitious revenue target that opponents describe as unrealistically high.

Bottom line for voters

Proposition 38 presents a deliberate trade‑off: a targeted, state‑backed investment in immunology and immunotherapy with strong accountability features and a distinctive discount for California patients, balanced against long‑term debt obligations and concerns about exclusivity and governance. Voters should weigh the fiscal commitments (the annual debt service and total cost), the transparency and distribution questions (the 4.2B disease set‑aside and the single‑institute allocation with UCLA’s revenue share), and the availability of alternative funding approaches that could fund broader research priorities or a state‑funded NIH‑style agency.

For readers seeking the official material, links to the Secretary of State’s voter information guides and LAO analyses are provided, along with non‑partisan summaries from Ballotpedia, CalMatters, and the League of Women Voters Easy Voter Guide.